All In Biotech

Drug Trial Radar · NCT05240612

A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)

A Clinical Pharmacological Study of MT-3921 in Subjects With Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM)

Last checked: Nov 20, 2026Latest source record: Jan 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

May 2, 2022

Primary completion

Sep 14, 2023

Study completion Dec 28, 2023

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Feb 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purposes of this study is to assess the safety, tolerability, and pharmacokinetics of MT-3921 in subjects with Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy(HAM). Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.

Conditions

  • HTLV-1-Associated Myelopathy (HAM)

Interventions

  • MT-3921Biological

    Solution for infusion; Intravenous (IV)

  • PlaceboBiological

    Solution for infusion; Intravenous (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with adverse eventsTime frame: 36 weeks
  2. Percentage of subjects with adverse reactionsTime frame: 36 weeks
  3. Serum concentrations of MT-3921Time frame: PK samples will be collected at predose, 1.5 hours, 2, 4, 8, 12, 20 (predose and 1.5 hours), 24, 36 weeks post-dose.
  4. CSF concentrations of MT-3921Time frame: PK samples will be collected at 2, 4, 12, 24 weeks post-dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Marianna University Hospital

    Kawasaki-shi, Kanagawa, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.